{"id":"NCT00359983","sponsor":"GlaxoSmithKline","briefTitle":"Long-Term Antibody Persistence at 1, 3 and 5 Years After a Fourth Dose of GSK Biologicals' Hib-MenCY-TT Vaccine Compared to ActHIB","officialTitle":"A Study to Evaluate the Long-term Antibody Persistence at 1, 3 & 5 Years After the Administration of a Fourth Dose of Hib-MenCY-TT Vaccine Compared to ActHIB in Subjects Boosted in a Previous Study.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-09","primaryCompletion":"2007-11","completion":"2011-05","firstPosted":"2006-08-03","resultsPosted":"2012-07-20","lastUpdate":"2016-12-16"},"enrollment":270,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Neisseria Meningitidis","Haemophilus Influenzae Type b"],"interventions":[{"type":"BIOLOGICAL","name":"MenHibrix (Hib-MenCY-TT)","otherNames":["GSK biologicals' Hib-MenCY-TT"]},{"type":"BIOLOGICAL","name":"Hib conjugate vaccine (ActHIB)","otherNames":["ActHIB"]}],"arms":[{"label":"MenHibrix 4-dose group","type":"EXPERIMENTAL"},{"label":"ActHIB 4-dose group","type":"ACTIVE_COMPARATOR"},{"label":"ActHIB 3-dose + MenHibrix 4th-dose group","type":"EXPERIMENTAL"}],"summary":"This study is evaluating antibody persistence at 1, 3 \\& 5 years post-fourth dose (i.e., at 2, 4 \\& 6 years of age, respectively) in subjects vaccinated in a previous study.\n\nThis protocol posting deals with objectives \\& outcome measures of the extension phase at years 1, 3 and 5. The objectives \\& outcome measures of the first four doses are presented in a separate protocol posting (NCT00129129).\n\nThis protocol posting has been amended in order to comply with the FDA Amendment Act of September 26, 2007.","primaryOutcome":{"measure":"Number of Subjects With Anti- Polyribosylribitol Phosphate (Anti-PRP) Antibody Concentrations Greater Than or Equal to 0.15 Microgram Per Milliliter","timeFrame":"One year, three years, and five years after the fourth dose vaccination.","effectByArm":[{"arm":"MenHibrix 4-dose Group","deltaMin":116,"sd":null},{"arm":"ActHIB 4-dose Group","deltaMin":49,"sd":null},{"arm":"ActHIB 3-dose + MenHibrix 4th-dose Group","deltaMin":46,"sd":null}],"pValues":[]},"eligibility":{"minAge":"22 Months","sex":"ALL","healthyVolunteers":true,"inclusionCount":4,"exclusionCount":2},"locations":{"siteCount":21,"countries":["United States"]},"refs":{"pmids":["21806393","20072077","23340564"],"seeAlso":["https://www.clinicalstudydatarequest.com"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":138},"commonTop":[]}}